"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03755739","Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors for Immunotherapy of Advanced Solid Tumors",,"Recruiting","No Results Available","Hepatocarcinoma|Lung Cancer|Melanoma|Renal Cancer|Head and Neck Cancer|Pancreas Cancer|Ovarian Cancer|Colo-rectal Cancer|Cervical Cancer|Breast Cancer","Drug: Checkpoint inhibitor (CPI) such as Pembrolizumab","Overall survival|Complete response (CR) rate before or at Month 6|Progression-free survival|Duration of remission (DOR)|Disease control rate|Cause of death (COD) when appropriate","Second Affiliated Hospital of Guangzhou Medical University","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Local Checkpoint Inhibitors","November 1, 2018","November 1, 2033","November 1, 2033","November 28, 2018",,"February 17, 2020","The Second Affiliated Hospital of Guangzhou Medical University, Guanzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03755739"
2,"NCT02973789","Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)",,"Recruiting","No Results Available","Nonsmall Cell Lung Cancer","Device: NovoTTF-100L|Drug: Immune checkpoint inhibitors or docetaxel","Overall survival of patients treated with TTFields + docetaxel or immune checkpoint inhibitors vs. docetaxel or immune checkpoint inhibitors alone (superiority analysis)|Overall survival of patients treated with TTFields + docetaxel vs. docetaxel alone (superiority analysis)|Overall survival of patients treated with TTFields + immune checkpoint inhibitors vs. immune checkpoint inhibitors alone (superiority)|Overall Survival of patients treated with TTFields + docetaxel Vs. immune checkpoint inhibitors alone (non-inferiority analysis)|Progression-free survival of patients treated with docetaxel or immune checkpoint inhibitors + TTFields vs. docetaxel or immune checkpoint inhibitors alone, based on RECIST Criteria|Overall radiological response rate (based on RECIST criteria) of patients treated with docetaxel or Immune checkpoint inhibitors + TTFields vs. docetaxel or immune checkpoint inhibitors alone.|Quality of life using the EORTC QLQ C30 questionnaire with LC13 addendum|Analyses of the effects of NovoTTF-100L with each type of immune checkpoint inhibitor on overall survival and progression free survival|Analysis of the effects of NovoTTF-100L on overall survival and progression free survival within each histological subgroup (squamous and non-squamous)|The effect of treatment compliance with NovoTTF-100L on overall survival and progression free survival outcomes|Adverse events, severity and frequency based on Common Terminology Criteria for Adverse Events (CTCAE) V4.03","NovoCure Ltd.","All","22 Years and older   (Adult, Older Adult)","Phase 3","534","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EF-24","December 2016","December 2021","December 2021","November 25, 2016",,"May 28, 2020","Ironwood Cancer & Research Center, Chandler, Arizona, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|Saddleback Memorial Medical Center, Laguna Hills, California, United States|Dignity Health - Mercy Cancer Centers, Sacramento, California, United States|Sutter Institute for Medical Research, Sacramento, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Associated Neurologists of Southern CT, P.C., Fairfield, Connecticut, United States|Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|Adult Oncology Research, Orlando, Florida, United States|BRCR Medical Center INC, Plantation, Florida, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Illinois CancerCare, P.C., Peoria, Illinois, United States|Franciscan Health Indianapolis, Indianapolis, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|University Medical Center, Inc; DBA University of Louisville, Louisville, Kentucky, United States|Tulane Cancer Center, New Orleans, Louisiana, United States|CHRISTUS Health, Shreveport, Louisiana, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Tufts Medical Center, Division of Hematology and Oncology, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Clinical Oncology Associates, Farmington Hills, Michigan, United States|Detroit Clinical Research Center, Farmington Hills, Michigan, United States|Saint Joseph Mercy Health System, Ypsilanti, Michigan, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CHI Health Research Center, Omaha, Nebraska, United States|Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|Renown Regional Medical Center Institute for Cancer, Reno, Nevada, United States|Presbyterian Cancer Center, Albuquerque, New Mexico, United States|New York-Presbyterian/Queens Radiation Oncology, Flushing, New York, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Stony Brook Cancer Center, Stony Brook, New York, United States|Oncology Specialists of Charlotte, Charlotte, North Carolina, United States|W.G. Bill Hefner VA Med Center, Salisbury, North Carolina, United States|Piedmont Radiation Oncology, PA, Winston-Salem, North Carolina, United States|Summa Health, Akron, Ohio, United States|Vita Medical Associates, P.C., Bethlehem, Pennsylvania, United States|Geisinger Cancer Institute, Danville, Pennsylvania, United States|UT/Erlanger Oncology & Hematology, Chattanooga, Tennessee, United States|Christus Health Spohn Ministry, Corpus Christi, Texas, United States|Dallas VA Medical Center, Dallas, Texas, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, United States|Oncology Consultants, P.A., Houston, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Overlake Medical Center & Clinics, Bellevue, Washington, United States|UW Carbone Cancer Center, Madison, Wisconsin, United States|Ordensklinikum Linz GmbH, Linz, Austria|Uniklinikum Salzburg Landeskrankenhaus - Universitätsklinik für Innere Medizin III der PMU, Salzburg, Austria|Institut Jules Bordet - Department of Intensive Care and Thoracic Oncology, Brussels, Belgium|André Renard Clinic, Herstal, Belgium|AZ Sint Maarten, Mechelen, Belgium|McGill University Health Centre, Montréal, Quebec, Canada|Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, Quebec, Canada|Allan Blair Cancer Center, Regina, Saskatchewan, Canada|Thomayerova Nemocnice Dept. of Pneumology, Prague, Czechia|Všeobecná Fakultní Nemocnice, Prague, Czechia|Vitkovicka nemocnice, Vitkovice, Czechia|Centre Hospitalier de Beauvais, Beauvais, France|INSTITUT BERGONIE Centre Régional de Lutte Contre le Cancer, Bordeaux, France|Hospital Centre of Brittany SUDF (CHBS), Lorient, France|CHU de Nîmes ICG. - Service de pneumologie, Nîmes, France|Hôpital Saint-Louis, Paris, France|Hospital Centre of Saint-Quentin, Saint-Quentin, France|Universitätsklinikum Halle (Saale) - Klinik und Poliklinik für Innere Medizin IV Onkologie/Hämatologie, Halle (Saale), Germany|Azienda Sociosanitaria Ligure 3 (ASL 3), Genova, Italy|IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy|UOC Oncologia Medica Presidio Ospedaliero di Ravenna, Ravenna, Italy|ASST della Valle Olona - Presidio Ospedaliero di Saronno, Saronno, Italy|St Jansdal Ziekenhuis, Harderwijk, Netherlands|Erasmus Mc, Rotterdam, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|MS Clinsearch Specjalistyczny NZOZ, Lublin, Poland|Katedra i Klinika Onkologii; Szpital Kliniczny Przemienienia Pańskiego UM w Poznaniu, Poznan, Poland|Samodzielny Publiczny Wojewódzki Szpital Zespolony w Szczecinie, Oddział Onkologii Klinicznej i Chemioterapii, Szczecin, Poland|Centrum Terapii Współczesnej, Łódź, Poland|Hospital Universitario Arnau de Vilanova, Lleida, Catalonia, Spain|Hospital Quirón Teknon, Instituto Oncológico Dr. Rosell, Barcelona, Spain|HGU Gregorio Marañón, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital Universitario Málaga Regional. IBIMA, Málaga, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Universitari i Politécnic La Fe, Valencia, Spain|KS Winterthur, Medizinische Onkologie, Winterthur, Switzerland",,"https://ClinicalTrials.gov/show/NCT02973789"
3,"NCT02654587","Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor","ATALANTE 1","Recruiting","No Results Available","Non Small Cell Lung Cancer","Drug: OSE2101|Drug: Docetaxel|Drug: Pemetrexed","Overall Survival time (OS)|Disease Control Rate (DCR) at 6 months|QLQ-C30 (EORTC QLQ questionnaire): ""Global health status/QoL"" score based on questions 29|QLQ-LC13 (lung cancer module from EORTC QLQ questionnaire): time to 1st ≥ 10-point deterioration in (question 40), dyspnea (questions 33, 34, 35) or cough (question 31)|Progression Free Survival (PFS)|Objective Response Rate (ORR) (in Step 1 only)|DCR at 12 months (in Step 1 only)|Duration of Response (DR) (in Step 1 only)|Safety and tolerability profile compared to the control group","OSE Immunotherapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","363","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSE2101C301|2015-003183-36","February 2016","December 2021","December 2021","January 13, 2016",,"December 12, 2019","Genesis Cancer Center, Hot Springs, Arkansas, United States|East Valley Hematology and Oncology medical Group, Burbank, California, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Pennington Cancer Center, Baton Rouge, Louisiana, United States|Pontchartrain Cancer Center, Covington, Louisiana, United States|Touro Infirmary, New Orleans, Louisiana, United States|North Mississippi Medical Center (NMMC)-Hematology and Oncology Clinic, Tupelo, Mississippi, United States|Meridian Health, Neptune, New Jersey, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Robert W. Franz Cancer Center, Portland, Oregon, United States|Gesinger Medical Center, Danville, Pennsylvania, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States|Mary Crowley Cancer Research Center, Dallas, Texas, United States|Millenium Oncology, Houston, Texas, United States|Nemocnice Jihlava, Onkologické oddelení, Jihlava, Czechia|Krajská nemocnice Liberec, Liberec, Czechia|Institut onkologie a rehablilitace na Plesi, Nová Ves Pod Pleší, Czechia|Klinika tuberkulózy a respiracních nemocí, FNO, Ostrava, Czechia|Pardubická krajská nemocnice, Pardubice, Czechia|Všeobecná Fakultní nemocnice, Praha, Czechia|Masarykova nemocnice v Usti nad Labem, Usti nad Labem, Czechia|Institut Saint Catherine, Avignon, France|Hôpital Avicenne, Bobigny, France|Institut Bergonié, Bordeaux, France|CHGU Morvan - Brest, Brest, France|Hôpital Louis Pradel, Bron, France|Centre de Lutte Contre le Cancer François Baclesse, Caen, France|Centre Hospitalier de Cholet, Cholet, France|Hôpital intercommunal de Créteil, Créteil, France|Centre de lutte contre le cancer Georges-François Leclerc (CGFL Dijon), Dijon, France|CHU Grenoble, Grenoble, France|Clinique Victor Hugo, Le Mans, France|Centre Hospitalier du Mans, Le Mans, France|Hopital Albert Calmette, Lille, France|Paoli-Calmettes Institute, Marseille, France|CHU Montpellier, Montpellier, France|Hôpital Emile Muller, Mulhouse, France|Centre Catherine de Sienne, Nantes, France|Hôpital Saint-Louis, Paris, France|Hôpital Européens Georges Pompidou (HEGP), Paris, France|Hôpital Bichat - Claude-Bernard, Paris, France|CHU de Rennes - Hôpital Pontchaillou, Rennes, France|Hôpital d'Instruction des Armées Bégin, Saint Mandé, France|Centre Paul Strauss (CLCC), Strasbourg, France|CHU de Strasbourg - Hôpital Civil, Strasbourg, France|Hôpital Larrey - CHU de Toulouse, Toulouse, France|Centre Hospitalier Régional Universitaire de Tours, Tours, France|Centre Hospitalier Troyes, Troyes, France|Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France|Institut Gustave Roussy (IGR), Villejuif, France|UniversitätsKlinikum Heidelberg, Bergheim, Germany|Krankenhaus Mehrheit - Kliniken der Stadt Köln - Lungenklinik, Cologne, Germany|SRH Wald-Klinikum Gera Thorax und Gefäßchirurgie Angiologie, Gera, Germany|Klinik für Innere Medizin II Hospital Martha-Maria Halle-Dölau gGmbH, Halle, Germany|German Cancer Research Center (DKFZ), Heidelberg, Germany|Lungenkrebszentrum an der Lungenklinik Hemer Deutscher Gemeinschafts-Diakonieverband GmbH, Hemer, Germany|Klinikum Bogenhausen Städtisches Klinikum München GmbH, Munich, Germany|Pius-Hospital Oldenburg Klinik für Hämatologie und Onkologie, Oldenburg, Germany|Universitätsklinikum Tübingen Medizinische Klinik II, Tubingen, Germany|Klinik für Innere Medizin II Universitätsklinikum Ulm, Ulm, Germany|HELIOS Klinikum Wuppertal Medizinische Klinik 1 für Hämatologie Onkologie Nephrologie, Wuppertal, Germany|Magyar Honvedseg Egeszsegugyi Kozpont II szamu telephely, Budapest, Hungary|Országos Korányi TBC és Pulmonológiai Intézet IV Tüdőbelosztály, Budapest, Hungary|Országos Korányi TBC és Pulmonológiai Intézet XI Tüdőbelosztály, Budapest, Hungary|Országos Korányi TBC és Pulmonológiai Intézet XIV Tüdőbelosztály, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|Semmelweis Egyetem Altalanos Orvostudományi Kar Pulmonologiai Klinika, Budapest, Hungary|Csongrad Megyei Mellkasi Betegsegek Szakkorháza I Tüdőosztály, Deszk, Hungary|Miskolci Sugárterápiás és Klinikai Onkológiai Intézet, Miskolc, Hungary|CRU Hungary Kft., Miskolc, Hungary|Matrai Gyogyintézet, Mátraháza, Hungary|Department of Pulmonology and Thoracic Oncology, Székesfehérvár, Hungary|Soroka University Medical Center, Be'er Sheva, Israel|Rambam Health Care Campus, Haifa, Israel|Hadassah Campus Ein Kerem, Jerusalem, Israel|Meir Medical Center, Kefar Saba, Israel|Rabin (Belinson) Medical Center, Petah tikva, Israel|Ziv MC, HaRambam Rd., Safed, Israel|Sourasky Medical Center (Ichilov Hospital), Tel Aviv, Israel|IRCCS Oncologico Giovanni Paolo II, Bari, Italy|Unità Operativa di Oncologia dell'Ospedale Vito Fazzi di Lecce, Piazza Muratore, Lecce, Italy|Oncologia medica, Legnano, Italy|Azienda USL 2 Lucca - Dipartimento Oncologico, Lucca, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T), Meldola, Italy|U.O.C. Pneumologia a indirizzo oncologico, Presidio Ospedaliero Monaldi - Azienda Ospedaliera dei Colli - Via Leonardo Bianchi, Napoli, Italy|Istituto Oncologico Veneto, IRCCS, Padova, Italy|Ospedale di Perugia - Oncologia medica, Perugia, Italy|Azienda Ospedaliero Universitaria pisana Pneumologia 2, Pisa, Italy|U.O Oncologia ed Ematologia, Ospedale Santa Maria delle Croci, Ravenna, Italy|U.O. Oncologia Ospedale Infermi, Rimini, Italy|UOC di Oncologia Medica, Policlinico Universitario Campus Biomedico, Roma, Italy|Ospedale Nuovo Regina Margherita, Roma, Italy|Policlinico Santa Maria alle Scotte, Siena, Italy|Ospedale Civile Maggiore, Verona, Italy|Hospicjum im. Ks. Eugeniusza Dutkiewicza SAC, Gdansk, Poland|Klinika Onkologii i Radioterapii , Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland|Przychodnia Lekarska ""KOMED"", Konin, Poland|""Oddział Onkologii z Pododdziałem Chemioterapii Nowotworów Płuc Samodzielny Publiczny Zespół Gruźlicy i Chorób Płuc w Olsztynie"", Olsztyn, Poland|Mazowieckie Centrum Leczenia chorób Płuc i Gruźlicy, Otwock, Poland|Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego Im. Karola Marcinkowskiego Oddział Chemioterapii, Poznań, Poland|Wojewódzki Szpital Zespolony , Oddział Chemioterapii Nowotworów, Toruń, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Specjalistyczny Szpital Im. Prof. Alfreda Sokołowskiego, Zdunowo, Poland|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Quirón Dexeus, Barcelona, Spain|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Hospital Universitario Germans Trias i Pujol, Barcelona, Spain|""Complejo Hospitalario Universitario A Coruna (CHUAC)"", La Coruña, Spain|""Hospital Universitario Fundacion Jimenez Diaz"", Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz Servicio de Oncología Médica, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda Servicio de Oncología Médica Consultas externas, 2ª planta, Madrid, Spain|Hospital de Mataro, Mataró, Spain|Hospital Universitario Carlos Haya, Málaga, Spain|""Hospital Universitario Miguel Servet"", Zaragoza, Spain|Cheltenham General Hospital, Cheltenham, United Kingdom|Medway Maritime Hospital, Gillingham, United Kingdom|Guys' Hospital, London, United Kingdom|Sarah Cannon Research Institue London, London, United Kingdom|Charring Cross Hospital, Imperial College NHS Foundation Trust, London, United Kingdom|The Chrisitie, Manchester, United Kingdom|Milton Keynes Hospital, Milton Keynes, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02654587"
4,"NCT03906071","Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer",,"Recruiting","No Results Available","Metastatic Non-Squamous Non-Small Cell Lung Cancer","Biological: Nivolumab|Drug: Sitravatinib|Drug: Docetaxel","Overall Survival (OS)|Adverse Events (AEs)|Objective Response Rate (ORR)|Progression-Free Survival (PFS)","Mirati Therapeutics Inc.|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","532","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","516-005","July 15, 2019","April 2022","December 2022","April 8, 2019",,"May 14, 2020","Alabama Oncology - Grandview, Birmingham, Alabama, United States|Clearview Cancer Institute, Huntsville, Alabama, United States|The Oncology Institute of Hope and Innovation - Tucson, Tucson, Arizona, United States|Yuma Regional Medical Center, Yuma, Arizona, United States|Saint Bernards Medical Center, Jonesboro, Arkansas, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|The Oncology Institute of Hope and Innovation - Corona, Corona, California, United States|California Cancer Associates for Research and Excellence - Fresno Cancer Center, Fresno, California, United States|Saint Joseph Heritage Healthcare - Virginia K. Crosson Cancer Center, Fullerton, California, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|Redlands Hematology Oncology, Redlands, California, United States|California Cancer Associates for Research and Excellence - San Marcos, San Marcos, California, United States|The Oncology Institute of Hope and Innovation - Thousand Oaks, Thousand Oaks, California, United States|The Oncology Institute of Hope and Innovation - Whittier, Whittier, California, United States|Sisters of Charity of Leavenworth Health St. Mary's, Grand Junction, Colorado, United States|Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States|Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, United States|Florida Cancer Specialists & Research Institute, Fort Myers, Florida, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Cancer Institute of Florida - Orlando, Orlando, Florida, United States|BRCR Medical Center Inc, Plantation, Florida, United States|SCRI - Florida Cancer Specialists - North Region Research Office, Sarasota, Florida, United States|SCRI - Florida Cancer Specialists - Panhandle Research Office, Tallahassee, Florida, United States|SCRI - Florida Cancer Specialists - West Palm Beach, West Palm Beach, Florida, United States|Piedmont Cancer Institute, Atlanta, Georgia, United States|John B. Amos Cancer Center Research, Columbus, Georgia, United States|Northwest Georgia Oncology Centers - Marietta, Marietta, Georgia, United States|Straub Medical Center, Honolulu, Hawaii, United States|Swedish Covenant Hospital, Chicago, Illinois, United States|Evanston Hospital, Evanston, Illinois, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|Healthcare Research Network - Tinley Park, Tinley Park, Illinois, United States|Goshen Center for Cancer Care, Goshen, Indiana, United States|Indiana University Health Arnett Cancer Care, Lafayette, Indiana, United States|The Richard and Annette Bloch Cancer Care Pavilion and Westwood Medical Pavilion, Westwood, Kansas, United States|Commonwealth Cancer Center, Danville, Kentucky, United States|Norton Cancer Institute - Broadway, Louisville, Kentucky, United States|New England Cancer Specialists, Scarborough, Maine, United States|Maryland Oncology Hematology - Rockville Aquilino Cancer Center, Rockville, Maryland, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Minnesota Oncology Hematology, Coon Rapids, Minnesota, United States|Park Nicollet - Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Kansas City Care Health Center - Research Medical Campus, Kansas City, Missouri, United States|Saint Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Methodist Hospital - Omaha, Omaha, Nebraska, United States|The Oncology Institute of Hope and Innovation - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Summit Medical Group - Florham Park Campus, Florham Park, New Jersey, United States|Regional Cancer Care Associates - Little Silver, Little Silver, New Jersey, United States|Regional Cancer Care Associates - Sparta, Sparta, New Jersey, United States|Broome Oncology, Johnson City, New York, United States|Stony Brook University Cancer Center, Stony Brook, New York, United States|Oncology Hematology Care - Blue Ash, Cincinnati, Ohio, United States|Tricounty Hematology and Oncology- Massillon, Massillon, Ohio, United States|Toledo Clinic Cancer Center, Toledo, Ohio, United States|SCRI - Tennessee Oncology - Nashville - Centennial, Nashville, Tennessee, United States|Texas Oncology - South Austin, Austin, Texas, United States|Texas Oncology - Methodist Dallas Cancer Center, Dallas, Texas, United States|Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology - Denton South, Denton, Texas, United States|Millennium Physicians - North Houston, Houston, Texas, United States|Texas Oncology - McKinney, McKinney, Texas, United States|Texas Oncology - Sherman, Sherman, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Hematology Oncology Associates of Fredericksburg, Fredericksburg, Virginia, United States|Overlake Medical Center and Clinics, Bellevue, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Northwest Cancer Specialists, Vancouver, Washington, United States|University Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|Froedtert Hospital - Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03906071"
5,"NCT03469960","Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr","DICIPLE","Recruiting","No Results Available","Non-Small Cell Lung Cancer Metastatic","Drug: Ipilimumab|Drug: Nivolumab","Progression Free Survival (PFS1)|Progression Free Survival (PFS2)|Quality of life|Overall survival (OS)|Biological correlative exploratory studies (PD-L1)|Biological correlative exploratory studies (PD-L1 H score)|Biological correlative exploratory studies (CD3/CD8)|Biological correlative exploratory studies (neutrophil)|Biological correlative exploratory studies (cytokines)|Biological correlative exploratory studies (chemokines)","Intergroupe Francophone de Cancerologie Thoracique","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","1360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IFCT-1701|2017-002540-33","May 2, 2018","May 2023","May 2023","March 19, 2018",,"September 4, 2019","Amiens - CHU, Amiens, France|Angers - CHU, Angers, France|Annecy - CH, Annecy, France|Argenteuil -CH, Argenteuil, France|Avignon - CH, Avignon, France|Bordeaux - Polyclinique Nord, Bordeaux, France|Boulogne - Ambroise Paré, Boulogne-Billancourt, France|Caen - CHU Côte de Nacre, Caen, France|Cahors - CH, Cahors, France|CH de Pontoise, Cergy Pontoise, France|CH Chambery, Chambery, France|CH de Chauny, Chauny, France|CH, Cholet, France|Clamart - Hôpital Percy, Clamart, France|Clermont Ferrand - CHU, Clermont Ferrand, France|Colmar - CH, Colmar, France|Dijon - CAC, Dijon, France|CHRU Grenoble, Grenoble, France|La Roche Sur Yon - CH, La Roche Sur Yon, France|Centre Hospitalier - Pneumologie, Le Mans, France|CHRU de Lille, Lille, France|CHU de Limoges, Limoges, France|CH Lyon Sud - Pneumologie, Lyon, France|Institut Paoli Calmette, Marseille, France|Marseille - Hôpital Européen, Marseille, France|Mont de Marsan - CH, Mont de Marsan, France|Mulhouse - CH, Mulhouse, France|Nantes - Centre René Gauducheau, Nantes, France|Centre Antoine Lacassagne, Nice, France|CHU Nîmes, Nîmes, France|Orléans - CH, Orléans, France|AP-HP Hopital Tenon - Pneumologie, Paris, France|AP-HP Hôpital Bichat, Paris, France|GH Paris Saint-Joseph, Paris, France|Hôpital Saint Louis APHP, Paris, France|Paris - Institut Curie, Paris, France|Rouen - CHU, Rouen, France|Saint Quentin - CH, Saint Quentin, France|Centre René Huguenin, Saint-Cloud, France|HIA Begin, Saint-Mandé, France|ICL Lucien Neuwirth, Saint-Priest-en-Jarez, France|Suresnes - Hopital Foch, Suresnes, France|Toulon - CHI, Toulon, France|CHU Toulouse, Toulouse, France|CHRU de Tours, Tours, France|Versailles - CH, Versailles, France|CH de Villefranche - Pneumologie, Villefranche, France",,"https://ClinicalTrials.gov/show/NCT03469960"
6,"NCT04157985","Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors",,"Recruiting","No Results Available","Advanced Solid Tumors|NSCLC|Bladder Cancer|HNSCC|Renal Cancer|Melanoma|Anal Cancer|Colorectal Cancer|Cholangiocarcinoma|Gastric Cancer|Hepatocellular Carcinoma","Drug: Continue PD-1/PD-L1 Inhibitors treatment|Other: Discontinue PD-1/PD-L1-1 inhibitor","Time to next treatment|Incidence of irAEs (Immune-Related Adverse Events)|Overall Survival (OS)|Best Objective Response (BOR)","Antoinette J Wozniak|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 3","578","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-135","November 15, 2019","October 31, 2021","October 31, 2021","November 8, 2019",,"December 4, 2019","UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04157985"
7,"NCT04338269","A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment","CONTACT-03","Not yet recruiting","No Results Available","Carcinoma, Renal Cell","Drug: Atezolizumab|Drug: Cabozantinib","Progression-Free Survival (PFS), as assessed by Independent Review Facility (IRF)|Overall survival (OS)|PFS Assessed by the Investigators (INV-PFS)|Investigator Assessed Objective Response Rate (INV-ORR)|IRF Assessed Objective Response Rate (IRF-ORR)|Investigator Assessed Duration of Objective Response (INV-DOR)|IRF Assessed DOR (IRF-DOR)|Percentage of Participants With Adverse Events|Atezolizumab Concentrations|Cabozantinib Concentrations|Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab|Number of ADAs to Atezolizumab","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WO41994","July 31, 2020","December 31, 2022","November 29, 2024","April 8, 2020",,"April 8, 2020","Zeisigwaldkliniken Bethanien, Chemnitz, Germany|Klinikum der Johann Wolfgang Goethe-Universitaet; Urologie und Kinderurologie, Frankfurt, Germany|Universitaetsklinikum Freiburg; Urology, Freiburg, Germany|Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie, Halle (Saale), Germany|Uniklinik-Eppendorf; Klinik U Poliklinik F Urologie, Hamburg, Germany|Medizinische Hochschule Hannover; Klinik für Urologie und Onkologische Urologie, Hannover, Germany|Universitaetsklinikum Muenster; Urology, Muenster, Germany|Klinikum rechts der Isar der TU München; Urologische Klinik und Poliklinik, München, Germany|Universitätsklinikum Tübingen; Klinik für Urologie, Tübingen, Germany|Universitätsklinikum Ulm; Klinik für Urologie, Ulm, Germany|Chungnam National University Hospital, Daejeon, Korea, Republic of|National Cancer Center, Gyeonggi-do, Korea, Republic of|CHA Bundang Medical Center, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Pusan National University Yangsan Hospital, Gyeongsangnam-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Medical Center, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|MEDSI Clinical Hospital on Pyatnitsky Highway; Department of antitumor drug therapy, Moscow, Moskovskaja Oblast, Russian Federation|SBIH ""Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM"", Moskva, Moskovskaja Oblast, Russian Federation|TSBHI Altai Territorial oncological dispensary, Barnaul, Russian Federation|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, Russian Federation|Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation|Medical Center Avicenna; Urology, Novosibirsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04338269"
8,"NCT03977571","Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial","NORDIC-SUN","Not yet recruiting","No Results Available","Kidney Cancer|Renal Cell Carcinoma Metastatic|Synchronous Neoplasm","Procedure: Cytoreductive nephrectomy|Drug: Nivolumab|Drug: Ipilimumab|Other: Tissue sampling","Overall survival|Progression free survival|Time to subsequent systemic therapy|Objective response rate|Rate of patients meeting randomization criteria|Fractional percentage of tumor volume (ratio of primary tumor measurement to total sum of target lesions) to survival outcome in deferred cytoreductive nephrectomy patients and no surgery patients|Number of participants with treatment-related adverse events as by Common Terminology Criteria for Adverse Events version 5.0.|Number of participant with surgical morbidity assessed according to the Clavien-Dindo classification of surgical complications|Tumor infiltrating lymphocytes baseline and after surgery compared with OS, PFS, TST, ORR|Immune subsets in blood measured by flowcytometry in serial samples compared with OS, PFS, TST, ORR.|Genetic profile of circulation tumor DNA measured by Next generation sequencing (NGS), compared with OS, PFS, TST, ORR.|Genetic profile of primary tumor tissue measured by measured by NGS compared with OS, PFS, TST, ORR.|Profile of gut microbiome measured by NGS compared OS, PFS, TST, ORR.","Frede Donskov|Aarhus University Hospital|University of Aarhus","All","18 Years and older   (Adult, Older Adult)","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NORDIC-SUN|2019-001685-14","June 1, 2020","September 1, 2025","September 1, 2025","June 6, 2019",,"April 24, 2020","Aarhus University Hospital, Department of oncology, Aarhus, Central Region Of Denmark, Denmark|Department of Oncology, Herlev Hospital, Herlev, Denmark|Department of Oncology, Odense University Hospital, Odense, Denmark",,"https://ClinicalTrials.gov/show/NCT03977571"
9,"NCT03827044","Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer","POLEM","Recruiting","No Results Available","POLE Exonuclease Mutant Colon Cancer|Microsatellite Instability|Stage III Colon Cancer","Drug: Avelumab","Primary End point: Disease Free survival|Secondary End Point: Overall Survival|Secondary End Points: Quality of Life|Secondary End Points: Toxicity of Investigational Medicinal Product according to the NCI-CTCAE (Common Terminology Criteria for Adverse Events) version 4.0.","Royal Marsden NHS Foundation Trust|University of Surrey|University of Oxford|Merck KGaA, Darmstadt, Germany","All","18 Years and older   (Adult, Older Adult)","Phase 3","402","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCR 4673 POLEM","August 31, 2018","July 2024","July 2028","February 1, 2019",,"February 20, 2020","Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03827044"
10,"NCT04154956","SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients","CARMEN-LC03","Recruiting","No Results Available","Non-small Cell Lung Cancer Metastatic","Drug: SAR408701|Drug: Docetaxel","Progression free survival (PFS)|Overall Survival (OS)|Objective response rate (ORR)|Health related quality of life (HRQOL) - disease related symptoms|Health related quality of life (HRQOL) - physical function|Health related quality of life (HRQOL) - role function|Number of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)|Duration of response (DOR)","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","554","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC15858|2019-001273-81|U1111-1233-0781","February 6, 2020","April 2024","April 2024","November 7, 2019",,"June 1, 2020","Investigational Site Number 8400007, Bakersfield, California, United States|Investigational Site Number 8400004, Tinley Park, Illinois, United States|Investigational Site Number 8400003, Nashville, Tennessee, United States|Investigational Site Number 8400013, The Woodlands, Texas, United States|Investigational Site Number 0320004, Buenos Aires, Argentina|Investigational Site Number 0320009, Caba, Argentina|Investigational Site Number 0320005, Rosario, Argentina|Investigational Site Number 0320002, Salta, Argentina|Investigational Site Number 0360002, Blacktown, Australia|Investigational Site Number 0360003, Waratah, Australia|Investigational Site Number 0360001, Woolloongabba, Australia|Investigational Site Number 0560005, Brugge, Belgium|Investigational Site Number 0560002, Bruxelles, Belgium|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 0560003, Liège, Belgium|Investigational Site Number 1240003, Greenfield Park, Canada|Investigational Site Number 1240004, Montreal, Canada|Investigational Site Number 1520007, Santiago, Chile|Investigational Site Number 1520002, Santiago, Chile|Investigational Site Number 1520005, Temuco, Chile|Investigational Site Number 1520001, Viña Del Mar, Chile|Investigational Site Number 3480002, Budapest, Hungary|Investigational Site Number 3480003, Budapest, Hungary|Investigational Site Number 3480008, Farkasgyepü, Hungary|Investigational Site Number 3920011, Bunkyo-Ku, Japan|Investigational Site Number 3920012, Fukuoka-Shi, Japan|Investigational Site Number 3920017, Himeji-Shi, Japan|Investigational Site Number 3920001, Hirakata-Shi, Japan|Investigational Site Number 3920008, Kurume-Shi, Japan|Investigational Site Number 3920002, Nagoya-Shi, Japan|Investigational Site Number 3920015, Nagoya-Shi, Japan|Investigational Site Number 3920009, Natori-Shi, Japan|Investigational Site Number 3920013, Osaka Sayama-Shi, Japan|Investigational Site Number 3920003, Osaka-Shi, Japan|Investigational Site Number 3920014, Sakai-Shi, Japan|Investigational Site Number 3920016, Sapporo-Shi, Japan|Investigational Site Number 3920004, Sunto-Gun, Japan|Investigational Site Number 3920010, Ube-Shi, Japan|Investigational Site Number 3920007, Wakayama-Shi, Japan|Investigational Site Number 3920005, Yokohama-Shi, Japan|Investigational Site Number 4100006, Seoul, Korea, Republic of|Investigational Site Number 4100007, Seoul, Korea, Republic of|Investigational Site Number 4100003, Seoul, Korea, Republic of|Investigational Site Number 4100001, Seoul, Korea, Republic of|Investigational Site Number 4100004, Seoul, Korea, Republic of|Investigational Site Number 6160001, Warsaw, Poland|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430003, Saint -Petersburg, Russian Federation|Investigational Site Number 7920008, Adana, Turkey|Investigational Site Number 7920002, Adana, Turkey|Investigational Site Number 7920004, Ankara, Turkey|Investigational Site Number 7920003, Edirne, Turkey|Investigational Site Number 7920005, Istanbul, Turkey|Investigational Site Number 7920001, Istanbul, Turkey|Investigational Site Number 7920006, Istanbul, Turkey|Investigational Site Number 7920007, Izmir, Turkey|Investigational Site Number 7920009, Malatya, Turkey",,"https://ClinicalTrials.gov/show/NCT04154956"
11,"NCT04163237","Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer",,"Recruiting","No Results Available","Advanced Liver Cancer","Drug: PD-1|Drug: Sorafenib","Disease-free Survival|Overall Survival","Guangxi Medical University","All","Child, Adult, Older Adult","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GuangXiMU-HCC-PD1(2)","December 1, 2019","October 31, 2020","November 30, 2020","November 14, 2019",,"November 14, 2019","TaoBai, Nanning, Guangxi, China",,"https://ClinicalTrials.gov/show/NCT04163237"
12,"NCT03150875","A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC",,"Active, not recruiting","No Results Available","Non-small Cell Lung Cancer","Biological: IBI308|Drug: Docetaxel","OS (overall survival)|PFS (progression free survival)|ORR(objective response rate)|DOR(Duration of objective response)|DCR(Disease control rate)|AEs","Innovent Biologics (Suzhou) Co. Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","290","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CIBI308C301","September 1, 2017","November 2, 2018","December 31, 2021","May 12, 2017",,"April 15, 2020","Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|The First Affiliated Hospital Zhejiang University, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT03150875"
13,"NCT03598270","Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA)","ANITA","Recruiting","No Results Available","Recurrent Ovarian Carcinoma","Drug: Placebo|Drug: Carboplatin|Drug: Paclitaxel|Drug: Niraparib|Drug: Gemcitabine|Drug: Pegylated liposomal doxorubicin (PLD)|Drug: Atezolizumab","Progression-free survival (PFS)|Overall survival (OS)|Time to first subsequent therapy or death (TFST)|Time to second subsequent therapy or death (TSST)|Time to second progression or death (PFS2)|Incidence of Treatment Adverse Events|Patient-reported abdominal symptoms|Patient-reported outcomes (PROs) of function and health related quality of life (HRQoL)|Objective Response Rate (ORR)|Duration of response (DOR)|Progression-free survival (PFS) from the beginning of the maintenance phase in all patients, in patients in complete or partial response after completing chemotherapy and in patients with stable disease after completing chemotherapy|Progression Free Survival (PFS) and BRCA status|Overall Survival (OS) and BRCA status|Time to first subsequent therapy or death (TFST) and BRCA status|Objective Response Rate (ORR) and BRCA status|Duration of Response (DOR) and BRCA status|Characterize the pharmacokinetics (PK) of atezolizumab|Determine the incidence of anti-therapeutic antibody (ATAs)","Grupo Español de Investigación en Cáncer de Ovario|Hoffmann-La Roche|Tesaro, Inc.|AGO Study Group|Belgian Gynaecological Oncology Group|ARCAGY/ GINECO GROUP|The Israeli Society of Gynecologic Oncology|MaNGO","Female","18 Years and older   (Adult, Older Adult)","Phase 3","414","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ENGOT-Ov41/GEICO 69-O/ANITA|2018-000366-11|ENGOT-Ov41|GEICO 69-O","November 21, 2018","May 2023","November 2023","July 26, 2018",,"December 3, 2019","CHU St. Pierre, Brussels, Belgium|CHU UCL St. Luc, Brussels, Belgium|Grand Hôpital de Charleroi, Charleroi, Belgium|AZ Maria Middelares, Gent, Belgium|UZ Leuven, Leuven, Belgium|CHU de Liège, site Sart Tilman, Liège, Belgium|CHU Ambroise Paré, Mons, Belgium|CHU UCL Namur site St. Elisabeth, Namur, Belgium|Hochtaunus-Kliniken, Bad Homburg, Germany|Charité - Universitätsmedizin Berlin (CVK), Berlin, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Kliniken Essen-Mitte, Essen, Germany|Universitätsklinik Freiburg, Freiburg, Germany|Universitätsmedizin Greifswald, Greifswald, Germany|Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg, Germany|Diakovere Krankenhaus, Hannover, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Germany|Klinikum Kulmbach, Kulmbach, Germany|Universitätsfrauenklinik Köln, Köln, Germany|Universitätsklinikum Schleswig-Holstein, Lübeck, Germany|Universitätsklinikum Münster, Münster, Germany|MVZ Nordhausen, Nordhausen, Germany|Klinikum Oldenburg AöR, Oldenburg, Germany|ROMed Klinikum Rosenheim, Rosenheim, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Universitätsfrauenklinik Ulm, Ulm, Germany|HELIOS Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany|Spedali Civili, Brescia, Italy|Asst Lecco, Lecco, Italy|Istituto Europeo di Oncologia, Milano, Italy|I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|AO Città della Salute e della Scienza- Ospedale Sant'Anna, Torino, Italy|Ospedale Mauriziano Umberto I, Torino, Italy|Hospital de Sabadell, Sabadell, Barcelona, Spain|Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain|ICO Badalona, Badalona, Spain|H. Clínic Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital de la Vall d'Hebron, Barcelona, Spain|H Reina Sofía Cordoba, Cordoba, Spain|ICO Girona, Girona, Spain|ICO Hospitalet, Hospitalet del Llobregat, Spain|Hospital de León, León, Spain|Clinica Universitaria de Navarra, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Gregorio Marañon, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|H Morales Meseguer, Murcia, Spain|Complejo Hospitalario Regional de Málaga, Málaga, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|Hospital Virgen del Rocio, Sevilla, Spain|H La Fe de Valencia, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT03598270"
14,"NCT03673735","Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC","ADHERE","Not yet recruiting","No Results Available","Squamous Cell Head and Neck Carcinoma","Drug: Durvalumab|Radiation: radiotherapy|Drug: Placebo|Drug: Cisplatin","disease free survival|overall survival|Cumulative incidence of distant metastases|Cumulative incidence of loco-regional recurrence|Cumulative incidence of second cancers (all sites)|Rate of toxicity assessed by clinicians|Health-related quality of Life questionnaires: QLQ-C30","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Older Adult)","Phase 3","650","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EORTC 1735-HNCG|2018-002730-21","March 2019","July 2026","December 2027","September 17, 2018",,"October 4, 2018",,,"https://ClinicalTrials.gov/show/NCT03673735"
15,"NCT03427827","Camrelizumab (PD-1 Antibody) After Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma (PACIFIC-NPC)",,"Recruiting","No Results Available","Nasopharyngeal Neoplasms","Drug: Camrelizumab","disease-free survival|overall survival|distant metastasis-free survival|locoregional recurrence-free survival|adverse events (AEs) and severe adverse events (SAE)|quality of life (QoL)","Sun Yat-sen University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B2017-097-01","June 1, 2018","February 2022","February 2024","February 9, 2018",,"October 8, 2019","First People's Hospital of Foshan, Foshan, Guangdong, China|Guangzhou Medical University Cancer Hospital, Guangzhou, Guangdong, China|Panyu central hospital, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, China|Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China|Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China|Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China|Xiangya Hospital Central South University, Changsha, Hunan, China|Xijing Hospital, Fourth Military Medical University, Xi'an, Shanxi, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT03427827"
16,"NCT03729245","A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)",,"Recruiting","No Results Available","Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma","Biological: bempegaldesleukin|Drug: sunitinib|Biological: nivolumab|Drug: cabozantinib","ORR using mRECIST 1.1 by BICR in IMDC intermediate- or poor-risk patients|ORR per mRECIST 1.1 by BICR in IMDC all-risk patients|Overall survival (OS) in IMDC intermediate- or poor-risk patients|OS in IMDC all-risk patients|Progression-free survival (PFS) per mRECIST 1.1 by BICR in IMDC intermediate- or poor-risk patients|PFS per mRECIST 1.1 by BICR in IMDC all risk-patients|Incidence of treatment-related Adverse Events (AEs)|ORR per mRECIST 1.1 by BICR in biomarker population|PFS per mRECIST 1.1 by BICR in biomarker population|OS in biomarker population|Changes in cancer-related symptoms and quality-of-life in patients using the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy (NCCN/FACT) Symptom Index for Kidney Cancer (FKSI-19)","Nektar Therapeutics|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-214-09|CA045002","December 18, 2018","December 2021","June 2024","November 2, 2018",,"May 29, 2020","Investigator Site - Anchorage, Anchorage, Alaska, United States|Investigator Site - Goodyear, Goodyear, Arizona, United States|Investigator Site - Little Rock, Little Rock, Arkansas, United States|Investigator Site - Duarte, Duarte, California, United States|Investigator Site - Los Angeles, Los Angeles, California, United States|Investigator Site - Orange, Orange, California, United States|Investigator Site - Whittier, Whittier, California, United States|Investigator Site - Miami, Miami, Florida, United States|Investigator Site - Atlanta, Atlanta, Georgia, United States|Investigator Site - New Orleans, New Orleans, Louisiana, United States|Investigator Site - Baltimore, Baltimore, Maryland, United States|Investigator Site - Henderson, Henderson, Nevada, United States|Investigator Site - East Setauket, East Setauket, New York, United States|Investigator Site - New York, New York, New York, United States|Investigator Site - Kettering, Kettering, Ohio, United States|Investigator Site - Portland, Portland, Oregon, United States|Investigator Site - Allentown, Allentown, Pennsylvania, United States|Investigator Site - Bethlehem, Bethlehem, Pennsylvania, United States|Investigator Site - Hershey, Hershey, Pennsylvania, United States|Investigator Site - Philadelphia, Philadelphia, Pennsylvania, United States|Investigator Site - Philadelphia, Philadelphia, Pennsylvania, United States|Investigator Site - Pittsburgh, Pittsburgh, Pennsylvania, United States|Investigator Site - Chattanooga, Chattanooga, Tennessee, United States|Investigator Site - Houston, Houston, Texas, United States|Investigator Site - Salt Lake City, Salt Lake City, Utah, United States|Investigator Site - Fairfax, Fairfax, Virginia, United States|Investigator Site - Tacoma, Tacoma, Washington, United States|Investigator Site - Pergamino, Pergamino, Buenos Aires, Argentina|Investigator Site - Santa Rosa, Santa Rosa, La Pampa, Argentina|Investigator Site - Viedma, Viedma, Rio Negro, Argentina|Investigator Site - Rosario, Rosario, Santa Fe, Argentina|Investigator Site - Rosario, Rosario, Santa Fe, Argentina|Investigator Site - Buenos Aires, Buenos Aires, Argentina|Investigator Site - Buenos Aires, Buenos Aires, Argentina|Investigator Site - Buenos Aires, Buenos Aires, Argentina|Investigator Site - Córdoba, Córdoba, Argentina|Investigator Site - Córdoba, Córdoba, Argentina|Investigator Site - Córdoba, Córdoba, Argentina|Investigator Site - La Rioja, La Rioja, Argentina|Investigator Site - San Miguel De Tucumán, San Miguel De Tucumán, Argentina|Investigator Site - Orange, Orange, New South Wales, Australia|Investigator Site - Saint Leonards, Saint Leonards, New South Wales, Australia|Investigator Site - Sydney, Sydney, New South Wales, Australia|Investigator Site - Kurralta Park, Kurralta Park, South Australia, Australia|Investigator Site - Nedlands, Nedlands, Western Australia, Australia|Investigator Site - Salvador, Salvador, Bahia, Brazil|Investigator Site - Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil|Investigator Site - Curitiba, Curitiba, Parana, Brazil|Investigator Site - Natal, Natal, Rio Grande Do Norte, Brazil|Investigator Site - Ijuí, Ijuí, Rio Grande Do Sul, Brazil|Investigator Site - Lajeado, Lajeado, Rio Grande Do Sul, Brazil|Investigator Site - Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Investigator Site - Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Investigator Site - Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Investigator Site - Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Investigator Site - Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Investigator Site -, Rio Grande, Rio Grande Do Sul, Brazil|Investigator Site - Joinville, Joinville, Santa Catarina, Brazil|Investigator Site - Barretos, Barretos, Sao Paulo, Brazil|Investigator Site - Campinas, Campinas, Sao Paulo, Brazil|Investigator Site - Santo André, Santo André, Sao Paulo, Brazil|Investigator Site - Jaú, Jaú, São Paulo, Brazil|Investigator Site - Caxias Do Sul, Caxias Do Sul, Brazil|Investigator Site - Fortaleza, Fortaleza, Brazil|Investigator Site - Lages, Lages, Brazil|Investigator Site - Rio de Janeiro, Rio De Janeiro, Brazil|Investigator Site - San Paolo, San Paolo, Brazil|Investigator Site - São José Do Rio Preto, São José Do Rio Preto, Brazil|Investigator Site - São Paulo, São Paulo, Brazil|Investigator Site - São Paulo, São Paulo, Brazil|Investigator Site - Osorno, Osorno, Los Lagos, Chile|Investigator Site - Valdivia, Valdivia, Los Rios, Chile|Investigator Site - Rancagua, Rancagua, Chile|Investigator Site - Santiago, Santiago, Chile|Investigator Site - Santiago, Santiago, Chile|Investigator Site - Santiago, Santiago, Chile|Investigator Site - Santiago, Santiago, Chile|Investigator Site - Santiago, Santiago, Chile|Investigator Site - Santiago, Santiago, Chile|Investigator Site - Temuco, Temuco, Chile|Investigator Site - Viña Del Mar, Viña Del Mar, Chile|Investigator Site - Viña Del Mar, Viña Del Mar, Chile|Investigator Site - Beijing, Beijing, China|Investigator Site - Medellín, Medellín, Antioquia, Colombia|Investigator Site - Montería, Montería, Cordoba, Colombia|Investigator Site - Bogotá, Bogotá, Colombia|Investigator Site - Floridablanca, Floridablanca, Colombia|Investigator Site - Hong Kong, Hong Kong, Hong Kong|Investigator Site - Morelia, Morelia, Michoacan, Mexico|Investigator Site - Monterrey, Monterrey, Nuevo Leon, Mexico|Investigator Site - Monterrey, Monterrey, Mexico|Investigator Site - Monterrey, Monterrey, Mexico|Investigator Site - Puebla, Puebla, Mexico|Investigator Site - Zapopan, Zapopan, Mexico|Investigator Site - Auckland, Auckland, New Zealand|Investigator Site - Christchurch, Christchurch, New Zealand|Investigator Site - Trujillo, Trujillo, La LIbertad, Peru|Investigator Site - Lima, Lima, Peru|Investigator Site - Lima, Lima, Peru|Investigator Site - Lima, Lima, Peru|Investigator Site - Lima, Lima, Peru|Investigator Site - Barnaul, Barnaul, Russian Federation|Investigator Site - Chelyabinsk, Chelyabinsk, Russian Federation|Investigator Site - Kursk, Kursk, Russian Federation|Investigator Site - Moscow, Moscow, Russian Federation|Investigator Site - Obninsk, Obninsk, Russian Federation|Investigator Site - Omsk, Omsk, Russian Federation|Investigator Site - Pushkin, Pushkin, Russian Federation|Investigator Site - Rostov-on-Don, Rostov-on-Don, Russian Federation|Investigator Site - Saint Petersburg, Saint Petersburg, Russian Federation|Investigator Site - Saint Petersburg, Saint Petersburg, Russian Federation|Investigator Site - Saint Petersburg, Saint Petersburg, Russian Federation|Investigator Site - Volzhskiy, Volzhskiy, Russian Federation|Investigator Site - Yaroslavl, Yaroslavl, Russian Federation|Investigator Site - Singapore, Singapore, Singapore|Investigator Site - Singapore, Singapore, Singapore|Investigator Site - Singapore, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03729245"
17,"NCT02627963","A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC",,"Active, not recruiting","Has Results","Carcinoma, Renal Cell","Drug: tivozanib hydrochloride|Drug: Sorafenib","Progression-free Survival (PFS)|Overall Survival (OS)|Objective Response Rate (ORR)|Duration of Response (DOR)","AVEO Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","350","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AV-951-15-303","April 2016","December 2018","June 2021","December 11, 2015","February 20, 2020","February 20, 2020","University Of UA Cancer Center(UACC)/DH-SJHMC, Phoenix, Arizona, United States|Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|Arizona Oncology - Phoenix - Deer Valley Women's Center Loca, Phoenix, Arizona, United States|Arizona Oncology - Scottsdale, Scottsdale, Arizona, United States|City of Hope Comprehensive Breast Cancer Center, Duarte, California, United States|Long Beach Memorial Medical Center, Fountain Valley, California, United States|Marin Cancer Care, Greenbrae, California, United States|UCLA, Los Angeles, California, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Loyola University Medical Center, Maywood, Illinois, United States|Investigative Clinical Research of Indiana, Indianapolis, Indiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Midwest Cancer Center, Omaha, Nebraska, United States|Urology Cancer Center, PC, Omaha, Nebraska, United States|Comprehensive Cancer Center Of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Center Of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Center of Nevada, Las Vegas, Nevada, United States|Hackensack University Medical Center - John Theurer Cancer, Hackensack, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|New York Oncology Hematology, PC, Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|New York Oncology Hematology, P.C., Clifton Park, New York, United States|New York Presbyterian Hospital, New York, New York, United States|Columbia University Medical Center - Herbert Irving Pavilion, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Wake Forest University Baptist Medical Center (WFUBMC), Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio Cancer Specialists, Mansfield, Ohio, United States|North Coast Cancer Care, Inc, Sandusky, Ohio, United States|Wooster Specialty and Surgery Center, Wooster, Ohio, United States|St. Luke University Health Network, Easton, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|Texas Oncology - Austin Midtown, Austin, Texas, United States|Texas Oncology-Central Austin Cancer Center, Austin, Texas, United States|Texas Oncology - South Austin Cancer Center, Austin, Texas, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology - Fort Worth 12th Ave, Fort Worth, Texas, United States|Texas Oncology SW Fort Worth Cancer Center, Fort Worth, Texas, United States|Arizona Oncology Associates, PC - HAL, Fort Worth, Texas, United States|Comprehensive Cancer Centers of Nevada (CCCN), Fort Worth, Texas, United States|Comprehensive Cancer Centers of Nevada, Fort Worth, Texas, United States|Nebraska Cancer Specialists (NCS) - Midwest Cancer Center, Fort Worth, Texas, United States|Texas Oncology - El Paso Cancer Treatment Center, Fort Worth, Texas, United States|Texas Oncology-El Paso Cancer Treatment Center, Fort Worth, Texas, United States|Texas Oncology-Garland, Garland, Texas, United States|Baylor College of Medicine - Baylor Clinic, Houston, Texas, United States|Texas Oncology - Longview Cancer Center, Longview, Texas, United States|Texas Oncology, P.A., Plano, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States|UZ Antwerpen, Edegem, Antwerpen, Belgium|Institut Jules Bordet, Bruxelles, Brussels Capital Region, Belgium|Grand Hôpital de Charleroi - Site Notre-Dame, Charleroi, Hainaut, Belgium|CHU Ambroise Paré, Mons, Hainaut, Belgium|Jessa Ziekenhuis - Campus Virga Jesse, Hasselt, Limburg, Belgium|CHU Dinant Godinne UCL Namur, Yvoir, Namur, Belgium|UZ Gent, Gent, Oost-Vlaanderen, Belgium|AZ Sint-Jan Brugge - Oostende - Campus Sint-Jan, Brugge, West-Vlaanderen, Belgium|British Columbia Cancer Agency (BCCA), Vancouver, British Columbia, Canada|Dr. Leon Richard Oncology Centre, Moncton, New Brunswick, Canada|London Health Sciences Center, London, Ontario, Canada|Sunnybrook, Toronto, Ontario, Canada|Masarykuv onkologicky ustav, Brno, Brno-město, Czechia|FN Hradec Kralove, Hradec Kralove, Královéhradecký Kraj, Czechia|Fakultni nemocnice Olomouc, Olomouc, Olomoucký Kraj, Czechia|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|Herlev Hospital, Herlev, Capital, Denmark|Aarhus Universitetshospital, Aarhus C, Central Jutland, Denmark|Odense Universitetshospital, Odense, South Denmark, Denmark|Hopital Saint-André, Bordeaux Cedex, Gironde, France|CHRU de Tours - Hopital Bretonneau TOURS, Tours CEDEX 1, Indre-et-Loire, France|Institut de Cancerologie de la Loire, Saint-Priest-en-Jarez, Loire, France|Institut de Cancérologie de l'Ouest Site Paul Papin, Angers, Maine-et-Loire, France|Institut de cancérologie de Lorraine, Vandoeuvre Les Nancy, Meurthe-et-Moselle, France|centre Oscar Lambret, Lille, Nord-Pas-de-Calais, France|Clinique Victor Hugo, Le Mans, Pays-de-la-Loire, France|Institut Paoli-Calmettes, Marseille Cedex 09, France|Chu De Poitiers, Poitiers, France|ICO, Saint Herblain CEDEX, France|Institut Gustave Roussy, Villejuif, France|Universitätsklinikum Freiburg, Freiburg, Baden-Württemberg, Germany|Univesitaetsklinik Heidelberg, Heidelberg, Baden-Württemberg, Germany|Kliniken Nordoberpfalz AG, Klinikum Weiden, Weiden, Bayern, Germany|Johann Wolfgang Goethe Universität, Frankfurt am Main, Hessen, Germany|Evangelisches Krankenhaus Bielefeld, Bielefeld, Nordrhein-Westfalen, Germany|SZB Study Center University Hospital Bonn, Bonn, Nordrhein-Westfalen, Germany|Uniklinik Köln Klinik und Poliklinik für Urologie, Köln, Nordrhein-Westfalen, Germany|Universitätsklinikum des Saarlandes, Homburg, Saarland, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany|Jena University Hospital, Jena, Thüringen, Germany|Universitätsklinikum Aachen, Aachen, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Universität Tübingen, Tübingen, Germany|Pécsi Tudományegyetem Klinikai Központ, Pécs, Baranya, Hungary|Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház, Miskolc, Borsod-Abaúj-Zemplén, Hungary|Békés Megyei Pándy Kálmán Kórház, Gyula, Békés, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpo, Szeged, Csongrád, Hungary|Debreceni Egyetem Klinikai Központ, Debrecen, Hajdú-Bihar, Hungary|Szent Margit Kórház, Budapest, Hungary|Magyar Honvédség Egészségügyi Központ, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Országos Onkológiai Intézet, Budapest, Hungary|Egyesített Szent István és Szent László Kórház-Rendelőintéze, Budapest, Hungary|Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, Hungary|Markusovszky Egyetemi Oktatókórház, Szombathely, Hungary|Zala Megyei Korhaz, Zalaegerszeg, Hungary|Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Foggia, Italy|Irccs Irst, Meldola, Forli, Italy|Istituto Clinico Humanitas Rozzano, IRCCS, Rozzano, Milano, Italy|Usl 7 Siena - Ospedale Alta Valdelsa ASL TOSCANA SUD-EST, Poggibonsi, Siena, Italy|Istituto di Candiolo, IRCCS, Candiolo, Torino, Italy|Ospedale S.Donato, AUSL 8 di Arezzo, Arezzo, Italy|Centro di Riferimento Oncologico IRCCS, Aviano, Italy|AO Spedali Civili di Brescia, PO Spedali Civili, Brescia, Italy|P.O. Ss. Annunziata, Chieti, Italy|ASST-Istituti Ospitalieri di Cremona, AO di Cremona, Cremona, Italy|AOU Careggi, Firenze, Italy|IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca, Genova, Italy|Ospedale Vito Fazzi, ASL Lecce, Lecce, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Ieo, Irccs, Milano, Italy|AOU Policlinico di Modena, Modena, Italy|IRCCS Fondazione ""Giovanni Pascale"", Napoli, Italy|Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|PU Campus Bio-medico di Roma, Roma, Italy|Regina Elena, Istituto Nazionale dei Tumori, IFO, IRCCS, Roma, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Italy|Azienda Ospedaliera S. Maria di Terni, Terni, Italy|Europejskie Centrum Zdrowia Otwock, Szpital im. F. Chopina, Otwock, Mazowieckie, Poland|Centrum Onkologii - Instytut im. Marii Sklodowskiej - Curie, Warszawa, Mazowieckie, Poland|MAGODENT Sp. z o.o. Szpital Onkologiczno-Kardiologiczny, Warszawa, Mazowieckie, Poland|Szpital Specjalist w Brzozowie Podkarpacki Ośrodek Onkologiczny, Brzozow, Poland|COPERNICUS Podmiot Leczn. Sp z o.o.,Wojew. Centrum Onkologii, Gdansk, Poland|NZOZ Vesalius Sp. z o.o., Krakow, Poland|Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego, Wroclaw, Poland|H.G.U. de Elche, Elche, Alicante, Spain|H.U.Son Espases, Palma, Baleares, Spain|Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Institut Catalá d´Oncología (I.C.O.), L'Hospitalet De Llobregat, Barcelona, Spain|C.S. Parc Taulí, Sabadell, Barcelona, Spain|H.U.F. Alcorcón, Alcorcón, Madrid, Spain|H.U.P Hierro-Majadahonda, Majadahonda, Madrid, Spain|C.H. de Navarra, Pamplona, Navarra, Spain|H.del Mar, Barcelona, Spain|H.Sta.Creu i St.Pau, Barcelona, Spain|H.U.Vall d'Hebrón, Barcelona, Spain|H. Clinic de Barcelona, Barcelona, Spain|H.U. Reina Sofía, Córdoba, Spain|ICO-H.U.Dr.J.Trueta, Girona, Spain|C.H. de Jaén, Jaén, Spain|H.G.U. G. Marañón, Madrid, Spain|H.U. Infanta Leonor, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|H.C. S.Carlos, Madrid, Spain|H.U. F. Jiménez Díaz, Madrid, Spain|H.U. 12 de Octubre, Madrid, Spain|H.U. La Paz, Madrid, Spain|H. Madrid Norte Sanchinarro, Madrid, Spain|H.U. Virgen de la Victoria, Málaga, Spain|H.U.V. Macarena, Sevilla, Spain|F.I. Valenciano de Oncología, Valencia, Spain|H.U.P.La Fe, Valencia, Spain|H.U. Miguel Servet, Zaragoza, Spain|Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom|Beatson West Of Scotland Cancer Centre, Glasgow, Glasgow City, United Kingdom|Cheltenham General Hospital, Cheltenham, Gloucestershire, United Kingdom|Southampton University Hospitals Nhs Trust, Southampton, Hampshire, United Kingdom|East Lancashire Hospitals NHS Trust, Blackburn, Lancashire, United Kingdom|Lancashire Teaching Hospitals NHS Foundation Trust, Preston, Lancashire, United Kingdom|Royal Stroke Center, Stoke-on-Trent, Staffordshire, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom|St James's University Hospital / Leeds Teaching Hospitals, Leeds, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|Charing Cross Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Mount Vernon Cancer Care, Middlesex, United Kingdom|Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, United Kingdom|Churchill Hospital [Oncology], Oxford, United Kingdom|Singleton Hospital, Swansea, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02627963/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02627963/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02627963"
18,"NCT04334759","DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma","DREAM3R","Not yet recruiting","No Results Available","Mesothelioma|Pleural Mesothelioma|Malignant Pleural Mesothelioma","Drug: Durvalumab|Drug: Standard Chemotherapy","Overall Survival|Progression-Free Survival (PFS)|Objective Tumour Response Rate (OTRR)|Classify and grade participants adverse events as assessed by CTCAE V5.0|Health-Related Quality of Life (QOL): QLQ-C30|Health-Related QOL: LC29|Health-Related QOL: EQ-5D-5L|Health Care Usage Costs: Hospitalization|Health Care Usage Costs: Scheduled Visits to Health Professionals|Health Care Usage Costs: Medications","PrECOG, LLC.|AstraZeneca|Australasian Lung Cancer Trials Group|University of Sydney","All","18 Years and older   (Adult, Older Adult)","Phase 3","480","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DREAM3R|PrE0506|ALTG 18/001|CTC 0231","September 2020","November 2024","May 2025","April 6, 2020",,"April 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04334759"
